Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2907037,summated recovery rates,"After single intracaecal administration of [14C]rhein (25 mg kg-1) and [14C]rhein anthrone (20 mg kg-1) to rats, the summated recovery rates of 14C after five days were in urine 37(+/- 8.3)% and 2.8(+/- 0.4)% and in faeces 53(+/- 9.5)% and 95 (+/- 10.1)%, respectively.",Excretion and distribution of [14C]rhein and [14C]rhein anthrone in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907037/),%,37,7238,DB00157,NADH
,2907037,summated recovery rates,"After single intracaecal administration of [14C]rhein (25 mg kg-1) and [14C]rhein anthrone (20 mg kg-1) to rats, the summated recovery rates of 14C after five days were in urine 37(+/- 8.3)% and 2.8(+/- 0.4)% and in faeces 53(+/- 9.5)% and 95 (+/- 10.1)%, respectively.",Excretion and distribution of [14C]rhein and [14C]rhein anthrone in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907037/),%,2.8,7239,DB00157,NADH
,2907037,summated recovery rates,"After single intracaecal administration of [14C]rhein (25 mg kg-1) and [14C]rhein anthrone (20 mg kg-1) to rats, the summated recovery rates of 14C after five days were in urine 37(+/- 8.3)% and 2.8(+/- 0.4)% and in faeces 53(+/- 9.5)% and 95 (+/- 10.1)%, respectively.",Excretion and distribution of [14C]rhein and [14C]rhein anthrone in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907037/),%,53,7240,DB00157,NADH
,2907037,summated recovery rates,"After single intracaecal administration of [14C]rhein (25 mg kg-1) and [14C]rhein anthrone (20 mg kg-1) to rats, the summated recovery rates of 14C after five days were in urine 37(+/- 8.3)% and 2.8(+/- 0.4)% and in faeces 53(+/- 9.5)% and 95 (+/- 10.1)%, respectively.",Excretion and distribution of [14C]rhein and [14C]rhein anthrone in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907037/),%,95,7241,DB00157,NADH
,23400695,terminal half-life,Amrubicinol reached peak concentration 2-4 h after amrubicin administration and had a terminal half-life of 53 h.,Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23400695/),h,53,17320,DB00157,NADH
,23400695,molar ratio,The molar ratio of amrubicinol to amrubicin in blood was 0.67 on day 3.,Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23400695/),,0.67,17321,DB00157,NADH
,10509758,peak serum concentrations,"6AN reached peak serum concentrations of 80-90 microM and was cleared rapidly, with T1/2alpha and T1/2beta values of 7.4 and 31.3 min, respectively.","Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10509758/),μM,80-90,20523,DB00157,NADH
,10509758,T1/2alpha,"6AN reached peak serum concentrations of 80-90 microM and was cleared rapidly, with T1/2alpha and T1/2beta values of 7.4 and 31.3 min, respectively.","Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10509758/),min,7.4,20524,DB00157,NADH
,10509758,T1/2beta,"6AN reached peak serum concentrations of 80-90 microM and was cleared rapidly, with T1/2alpha and T1/2beta values of 7.4 and 31.3 min, respectively.","Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10509758/),min,31.3,20525,DB00157,NADH
,10509758,Bioavailability,Bioavailability was 80-100% with identical plasma pharmacokinetics after i.p. administration.,"Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10509758/),%,80-100,20526,DB00157,NADH
,22616762,bioavailability,The mean bioavailability was circa 14% and the mean clearance was circa 400 ml min(-1).,"Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22616762/),%,14,23228,DB00157,NADH
,22616762,clearance,The mean bioavailability was circa 14% and the mean clearance was circa 400 ml min(-1).,"Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22616762/),[ml] / [min],400,23229,DB00157,NADH
,12381684,t1/2,"Compared with Mitomycin C (MMC) and the experimental agent MeDZQ, EO9 was rapidly cleared from the systemic circulation (t1/2=1.8 min) whereas MMC and MeDZQ had significantly increased plasma t1/2 values (14 and 22 min respectively).",Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12381684/),min,1.8,24029,DB00157,NADH
,12381684,plasma t1/2,"Compared with Mitomycin C (MMC) and the experimental agent MeDZQ, EO9 was rapidly cleared from the systemic circulation (t1/2=1.8 min) whereas MMC and MeDZQ had significantly increased plasma t1/2 values (14 and 22 min respectively).",Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12381684/),min,14,24030,DB00157,NADH
,12381684,plasma t1/2,"Compared with Mitomycin C (MMC) and the experimental agent MeDZQ, EO9 was rapidly cleared from the systemic circulation (t1/2=1.8 min) whereas MMC and MeDZQ had significantly increased plasma t1/2 values (14 and 22 min respectively).",Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12381684/),min,22,24031,DB00157,NADH
,12381684,t1/2,EO9 was rapidly metabolized by red blood cells in vitro (t1/2=14.5 min) which must contribute to its rapid pharmacokinetic elimination in vivo whereas MMC and MeDZQ were metabolized at comparatively slower rates (t1/2>120 min and 77.0 min respectively).,Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12381684/),min,14.5,24032,DB00157,NADH
>,12381684,t1/2,EO9 was rapidly metabolized by red blood cells in vitro (t1/2=14.5 min) which must contribute to its rapid pharmacokinetic elimination in vivo whereas MMC and MeDZQ were metabolized at comparatively slower rates (t1/2>120 min and 77.0 min respectively).,Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12381684/),min,120,24033,DB00157,NADH
,12381684,t1/2,EO9 was rapidly metabolized by red blood cells in vitro (t1/2=14.5 min) which must contribute to its rapid pharmacokinetic elimination in vivo whereas MMC and MeDZQ were metabolized at comparatively slower rates (t1/2>120 min and 77.0 min respectively).,Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12381684/),min,77.0,24034,DB00157,NADH
,15718306,clearance,"At the MTD, the clearance and half-life (t(1/2)) of 17-AAG were 11.6 L/h/m(2) and 4.15 hours, respectively; whereas the active metabolite 17-aminogeldanamycin had a t(1/2) of 7.63 hours.",Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15718306/),[h·l] / [m(2],11.6,26864,DB00157,NADH
,15718306,half-life (t(1/2)),"At the MTD, the clearance and half-life (t(1/2)) of 17-AAG were 11.6 L/h/m(2) and 4.15 hours, respectively; whereas the active metabolite 17-aminogeldanamycin had a t(1/2) of 7.63 hours.",Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15718306/),h,4.15,26865,DB00157,NADH
,15718306,t(1/2),"At the MTD, the clearance and half-life (t(1/2)) of 17-AAG were 11.6 L/h/m(2) and 4.15 hours, respectively; whereas the active metabolite 17-aminogeldanamycin had a t(1/2) of 7.63 hours.",Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15718306/),h,7.63,26866,DB00157,NADH
,15718306,MTD,The MTD of weekly 17-AAG is 308 mg/m(2).,Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15718306/),[mg] / [m(2],308,26867,DB00157,NADH
,8615500,half-lives,"In rats, the pharmacokinetics and pharmacodynamics of MC-NaD and Dantrium were similar: half-lives of 3.1 h, volume distributions of 0.54 and 0.59 L/kg, and 95% effective dose (ED95) values for depression of skeletal muscle twitch height (ED95T) of 2.6 +/- 0.7 and 2.8 +/- 0.5 mg/kg.","Intravenous lecithin-coated microcrystals of dantrolene are effective in the treatment of malignant hyperthermia: an investigation in rats, dogs, and swine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8615500/),h,3.1,40031,DB00157,NADH
,8615500,volume distributions,"In rats, the pharmacokinetics and pharmacodynamics of MC-NaD and Dantrium were similar: half-lives of 3.1 h, volume distributions of 0.54 and 0.59 L/kg, and 95% effective dose (ED95) values for depression of skeletal muscle twitch height (ED95T) of 2.6 +/- 0.7 and 2.8 +/- 0.5 mg/kg.","Intravenous lecithin-coated microcrystals of dantrolene are effective in the treatment of malignant hyperthermia: an investigation in rats, dogs, and swine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8615500/),[l] / [kg],0.54,40032,DB00157,NADH
,8615500,volume distributions,"In rats, the pharmacokinetics and pharmacodynamics of MC-NaD and Dantrium were similar: half-lives of 3.1 h, volume distributions of 0.54 and 0.59 L/kg, and 95% effective dose (ED95) values for depression of skeletal muscle twitch height (ED95T) of 2.6 +/- 0.7 and 2.8 +/- 0.5 mg/kg.","Intravenous lecithin-coated microcrystals of dantrolene are effective in the treatment of malignant hyperthermia: an investigation in rats, dogs, and swine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8615500/),[l] / [kg],0.59,40033,DB00157,NADH
,8615500,depression of skeletal muscle twitch height (ED95T),"In rats, the pharmacokinetics and pharmacodynamics of MC-NaD and Dantrium were similar: half-lives of 3.1 h, volume distributions of 0.54 and 0.59 L/kg, and 95% effective dose (ED95) values for depression of skeletal muscle twitch height (ED95T) of 2.6 +/- 0.7 and 2.8 +/- 0.5 mg/kg.","Intravenous lecithin-coated microcrystals of dantrolene are effective in the treatment of malignant hyperthermia: an investigation in rats, dogs, and swine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8615500/),[mg] / [kg],2.6,40034,DB00157,NADH
,8615500,depression of skeletal muscle twitch height (ED95T),"In rats, the pharmacokinetics and pharmacodynamics of MC-NaD and Dantrium were similar: half-lives of 3.1 h, volume distributions of 0.54 and 0.59 L/kg, and 95% effective dose (ED95) values for depression of skeletal muscle twitch height (ED95T) of 2.6 +/- 0.7 and 2.8 +/- 0.5 mg/kg.","Intravenous lecithin-coated microcrystals of dantrolene are effective in the treatment of malignant hyperthermia: an investigation in rats, dogs, and swine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8615500/),[mg] / [kg],2.8,40035,DB00157,NADH
,8615500,E,"In swine, the ED95T values for MC-NaD and Dantrium were also similar (2.8 +/- 0.4 vs 2.7 +/- 0.6 mg/kg), but MC-D and Dantrium were only similar at doses more than 2.5 mg/kg (ED95T: 3.5 +/- 0.4 vs 2.7 +/- 0.5 mg/kg).","Intravenous lecithin-coated microcrystals of dantrolene are effective in the treatment of malignant hyperthermia: an investigation in rats, dogs, and swine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8615500/),,2,40036,DB00157,NADH
,8615500,E,"In swine, the ED95T values for MC-NaD and Dantrium were also similar (2.8 +/- 0.4 vs 2.7 +/- 0.6 mg/kg), but MC-D and Dantrium were only similar at doses more than 2.5 mg/kg (ED95T: 3.5 +/- 0.4 vs 2.7 +/- 0.5 mg/kg).","Intravenous lecithin-coated microcrystals of dantrolene are effective in the treatment of malignant hyperthermia: an investigation in rats, dogs, and swine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8615500/),,2,40037,DB00157,NADH
,8615500,ED95T,"In swine, the ED95T values for MC-NaD and Dantrium were also similar (2.8 +/- 0.4 vs 2.7 +/- 0.6 mg/kg), but MC-D and Dantrium were only similar at doses more than 2.5 mg/kg (ED95T: 3.5 +/- 0.4 vs 2.7 +/- 0.5 mg/kg).","Intravenous lecithin-coated microcrystals of dantrolene are effective in the treatment of malignant hyperthermia: an investigation in rats, dogs, and swine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8615500/),[mg] / [kg],3.5,40038,DB00157,NADH
,8615500,ED95T,"In swine, the ED95T values for MC-NaD and Dantrium were also similar (2.8 +/- 0.4 vs 2.7 +/- 0.6 mg/kg), but MC-D and Dantrium were only similar at doses more than 2.5 mg/kg (ED95T: 3.5 +/- 0.4 vs 2.7 +/- 0.5 mg/kg).","Intravenous lecithin-coated microcrystals of dantrolene are effective in the treatment of malignant hyperthermia: an investigation in rats, dogs, and swine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8615500/),[mg] / [kg],2.7,40039,DB00157,NADH
,2085346,half-life,AcDH-overloaded mouse red blood cells from donor animals were also injected intraperitoneally into compatible recipients (Balb/C) and 80 to 85% of these were found to enter into circulation within 24 hr and to circulate with a half-life of 6-7.3 days (normal half-life 11 days).,In vivo accelerated acetaldehyde metabolism using acetaldehyde dehydrogenase-loaded erythrocytes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085346/),d,6-7.3,55677,DB00157,NADH
,2085346,half-life,AcDH-overloaded mouse red blood cells from donor animals were also injected intraperitoneally into compatible recipients (Balb/C) and 80 to 85% of these were found to enter into circulation within 24 hr and to circulate with a half-life of 6-7.3 days (normal half-life 11 days).,In vivo accelerated acetaldehyde metabolism using acetaldehyde dehydrogenase-loaded erythrocytes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085346/),d,11,55678,DB00157,NADH
,10545412,peak levels,"In the case of skin and prostate, the peak levels of silibinin were 1.4 +/- 0.5 and 2.5 +/- 0.4, respectively, and were achieved 1 h after administration.","Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10545412/),,1.4,70929,DB00157,NADH
,10545412,peak levels,"In the case of skin and prostate, the peak levels of silibinin were 1.4 +/- 0.5 and 2.5 +/- 0.4, respectively, and were achieved 1 h after administration.","Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10545412/),,2.5,70930,DB00157,NADH
,10545412,elimination half-life (t((1/2))),The levels of both free and conjugated silibinin declined after 0.5 or 1 h in an exponential fashion with an elimination half-life (t((1/2))) of 57-127 min for free and 45-94 min for conjugated silibinin in different tissues.,"Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10545412/),min,57-127,70931,DB00157,NADH
,10545412,elimination half-life (t((1/2))),The levels of both free and conjugated silibinin declined after 0.5 or 1 h in an exponential fashion with an elimination half-life (t((1/2))) of 57-127 min for free and 45-94 min for conjugated silibinin in different tissues.,"Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10545412/),min,45-94,70932,DB00157,NADH
,18319359,Total g,Total ginsenoside content was 8.5 +/- 0.5%.,"Possible differential induction of phase 2 enzyme and antioxidant pathways by american ginseng, Panax quinquefolius. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18319359/),%,8.5,76338,DB00157,NADH
,17429625,systemic plasma clearance,"In vivo systemic plasma clearance values of dasatinib were 62, 26, 25, and 34 ml/min/kg in mouse, rat, dog, and monkey, respectively.",Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),[ml] / [kg·min],62,81997,DB00157,NADH
,17429625,systemic plasma clearance,"In vivo systemic plasma clearance values of dasatinib were 62, 26, 25, and 34 ml/min/kg in mouse, rat, dog, and monkey, respectively.",Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),[ml] / [kg·min],26,81998,DB00157,NADH
,17429625,systemic plasma clearance,"In vivo systemic plasma clearance values of dasatinib were 62, 26, 25, and 34 ml/min/kg in mouse, rat, dog, and monkey, respectively.",Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),[ml] / [kg·min],25,81999,DB00157,NADH
,17429625,systemic plasma clearance,"In vivo systemic plasma clearance values of dasatinib were 62, 26, 25, and 34 ml/min/kg in mouse, rat, dog, and monkey, respectively.",Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),[ml] / [kg·min],34,82000,DB00157,NADH
,17429625,Percent distribution,Percent distribution in blood cells ranged from 43% in mouse to 57% in dog.,Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),%,43,82001,DB00157,NADH
,17429625,Percent distribution,Percent distribution in blood cells ranged from 43% in mouse to 57% in dog.,Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),%,57,82002,DB00157,NADH
>,17429625,volumes of distribution,Dasatinib showed high volumes of distribution (>3 l/kg) and high serum protein binding values (>90%) in all four species tested.,Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),[l] / [kg],3,82003,DB00157,NADH
>,17429625,serum protein binding,Dasatinib showed high volumes of distribution (>3 l/kg) and high serum protein binding values (>90%) in all four species tested.,Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),%,90,82004,DB00157,NADH
,17429625,Oral bioavailability,Oral bioavailability of dasatinib ranged from 14% in the mouse to 34% in the dog.,Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),%,14,82005,DB00157,NADH
,17429625,Oral bioavailability,Oral bioavailability of dasatinib ranged from 14% in the mouse to 34% in the dog.,Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429625/),%,34,82006,DB00157,NADH
,21378203,MTD,MTD was 1430 μg/m(2)/day with reversible bone marrow suppression being dose limiting.,Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21378203/),[μg] / [d·m(2)],1430,82969,DB00157,NADH
,21378203,t(1/2),"Plasma pharmacokinetic analysis showed RH1 is rapidly cleared from blood (t(1/2) = 12.3 min), with AUC increasing proportionately with dose.",Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21378203/),min,12.3,82970,DB00157,NADH
,21378203,MTD,The MTD of 1430 μg/m(2)/day is the dose recommended for phase II trials.,Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21378203/),[μg] / [d·m(2)],1430,82971,DB00157,NADH
,649230,alpha-phase half-life,"After single 0.5-mg nad 1.0-mg i.v. injections, dihydroergotamine, as measured by a radioimmunoassay, disappeared quickly from the plasma of beagles, with a mean alpha-phase half-life of 1.32--1.91 min.",The pharmacokinetics of dihydroergotamine in the beagle. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649230/),min,1.32,88124,DB00157,NADH
,649230,beta-phase half-life,"Its short beta-phase half-life (mean, 40.79--70.13 min), a moderately low volume of ditribution at beta-phase (mean 1.50--3.46 L/kg) and a rather high plasma clearance value (mean, 311.67--587.88 ml/min) indicate a rapid elimination of the drug from the organism.",The pharmacokinetics of dihydroergotamine in the beagle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/649230/),min,40.79,88125,DB00157,NADH
,649230,volume of ditribution at beta-phase,"Its short beta-phase half-life (mean, 40.79--70.13 min), a moderately low volume of ditribution at beta-phase (mean 1.50--3.46 L/kg) and a rather high plasma clearance value (mean, 311.67--587.88 ml/min) indicate a rapid elimination of the drug from the organism.",The pharmacokinetics of dihydroergotamine in the beagle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649230/),[l] / [kg],1.50,88126,DB00157,NADH
,649230,plasma clearance,"Its short beta-phase half-life (mean, 40.79--70.13 min), a moderately low volume of ditribution at beta-phase (mean 1.50--3.46 L/kg) and a rather high plasma clearance value (mean, 311.67--587.88 ml/min) indicate a rapid elimination of the drug from the organism.",The pharmacokinetics of dihydroergotamine in the beagle. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649230/),[ml] / [min],311.67,88127,DB00157,NADH
,649230,urinary excretion,The 24-hr urinary excretion of dihydroergotamine was 2.7% of the 0.5-mg i.v. dose and 2.3% to 3.1% of the 1.0-mg i.v. dose.,The pharmacokinetics of dihydroergotamine in the beagle. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649230/),%,2.7,88128,DB00157,NADH
,649230,urinary excretion,The 24-hr urinary excretion of dihydroergotamine was 2.7% of the 0.5-mg i.v. dose and 2.3% to 3.1% of the 1.0-mg i.v. dose.,The pharmacokinetics of dihydroergotamine in the beagle. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649230/),%,2.3,88129,DB00157,NADH
,649230,urinary excretion,The 24-hr urinary excretion of dihydroergotamine was 2.7% of the 0.5-mg i.v. dose and 2.3% to 3.1% of the 1.0-mg i.v. dose.,The pharmacokinetics of dihydroergotamine in the beagle. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649230/),%,3.1,88130,DB00157,NADH
,30559136,area under the curve ratios,"The study showed good penetration of afabicin desphosphono into bone tissues, with mean area under the curve ratios for cortical bone-, cancellous bone-, bone marrow-, soft tissue-, and synovial fluid-to-total plasma concentrations of 0.21, 0.40, 0.32, 0.35, and 0.61, respectively.",Bone and Joint Tissue Penetration of the Staphylococcus-Selective Antibiotic Afabicin in Patients Undergoing Elective Hip Replacement Surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30559136/),,0.21,100431,DB00157,NADH
,30559136,area under the curve ratios,"The study showed good penetration of afabicin desphosphono into bone tissues, with mean area under the curve ratios for cortical bone-, cancellous bone-, bone marrow-, soft tissue-, and synovial fluid-to-total plasma concentrations of 0.21, 0.40, 0.32, 0.35, and 0.61, respectively.",Bone and Joint Tissue Penetration of the Staphylococcus-Selective Antibiotic Afabicin in Patients Undergoing Elective Hip Replacement Surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30559136/),,0.40,100432,DB00157,NADH
,30559136,area under the curve ratios,"The study showed good penetration of afabicin desphosphono into bone tissues, with mean area under the curve ratios for cortical bone-, cancellous bone-, bone marrow-, soft tissue-, and synovial fluid-to-total plasma concentrations of 0.21, 0.40, 0.32, 0.35, and 0.61, respectively.",Bone and Joint Tissue Penetration of the Staphylococcus-Selective Antibiotic Afabicin in Patients Undergoing Elective Hip Replacement Surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30559136/),,0.32,100433,DB00157,NADH
,30559136,area under the curve ratios,"The study showed good penetration of afabicin desphosphono into bone tissues, with mean area under the curve ratios for cortical bone-, cancellous bone-, bone marrow-, soft tissue-, and synovial fluid-to-total plasma concentrations of 0.21, 0.40, 0.32, 0.35, and 0.61, respectively.",Bone and Joint Tissue Penetration of the Staphylococcus-Selective Antibiotic Afabicin in Patients Undergoing Elective Hip Replacement Surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30559136/),,0.35,100434,DB00157,NADH
,30559136,area under the curve ratios,"The study showed good penetration of afabicin desphosphono into bone tissues, with mean area under the curve ratios for cortical bone-, cancellous bone-, bone marrow-, soft tissue-, and synovial fluid-to-total plasma concentrations of 0.21, 0.40, 0.32, 0.35, and 0.61, respectively.",Bone and Joint Tissue Penetration of the Staphylococcus-Selective Antibiotic Afabicin in Patients Undergoing Elective Hip Replacement Surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30559136/),,0.61,100435,DB00157,NADH
,28370165,half-life,The half-life of JPI-289 after intravenous or oral administration in rats was relatively long (1.4-1.5 hours) with 65.6% bioavailability.,"Neuroprotective effects of a novel poly (ADP-ribose) polymerase-1 inhibitor, JPI-289, in hypoxic rat cortical neurons. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28370165/),h,1.4-1.5,104222,DB00157,NADH
,28370165,half-life,The half-life of JPI-289 after intravenous or oral administration in rats was relatively long (1.4-1.5 hours) with 65.6% bioavailability.,"Neuroprotective effects of a novel poly (ADP-ribose) polymerase-1 inhibitor, JPI-289, in hypoxic rat cortical neurons. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28370165/),%,65.6,104223,DB00157,NADH
,28370165,bioavailability,The half-life of JPI-289 after intravenous or oral administration in rats was relatively long (1.4-1.5 hours) with 65.6% bioavailability.,"Neuroprotective effects of a novel poly (ADP-ribose) polymerase-1 inhibitor, JPI-289, in hypoxic rat cortical neurons. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28370165/),%,65.6,104224,DB00157,NADH
,28370165,IC50,The inhibitor strongly inhibited PARP-1 activity (IC50 =18.5 nmol/L) and cellular PAR formation (IC50 =10.7 nmol/L) in the nanomolar range.,"Neuroprotective effects of a novel poly (ADP-ribose) polymerase-1 inhibitor, JPI-289, in hypoxic rat cortical neurons. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28370165/),[nM] / [l],18.5,104225,DB00157,NADH
,28370165,IC50,The inhibitor strongly inhibited PARP-1 activity (IC50 =18.5 nmol/L) and cellular PAR formation (IC50 =10.7 nmol/L) in the nanomolar range.,"Neuroprotective effects of a novel poly (ADP-ribose) polymerase-1 inhibitor, JPI-289, in hypoxic rat cortical neurons. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28370165/),[nM] / [l],10.7,104226,DB00157,NADH
,32283915,IC50,We found that the gold(I)-derived complexes were active against L. infantum and L. braziliensis intracellular amastigotes with IC50 values ranging from 0.5 to 5.5 μM.,Preclinical Gold Complexes as Oral Drug Candidates to Treat Leishmaniasis Are Potent Trypanothione Reductase Inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32283915/),μM,0.5 to 5.5,114683,DB00157,NADH
,32283915,IC50,"All gold(I) complexes were potent inhibitors of trypanothione reductase (TR), with enzyme IC50 values ranging from 1 to 7.8 μM.",Preclinical Gold Complexes as Oral Drug Candidates to Treat Leishmaniasis Are Potent Trypanothione Reductase Inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32283915/),μM,1 to 7.8,114684,DB00157,NADH
,3355719,maximum metabolizing capacity,"The kinetics of 1,2-propanediol (PD) metabolism in vivo have been determined by employing the Michaelis-Menten rate equation; it was found that maximum metabolizing capacity was 8.33 mmole PD/kg/hr in the rat, which is equivalent to 1.06 kg/day for an average 70-kg human.",Kinetics of propylene glycol elimination and metabolism in rat. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3355719/),[mmole·pd] / [h·kg],8.33,115698,DB00157,NADH
,3355719,maximum metabolizing capacity,"The kinetics of 1,2-propanediol (PD) metabolism in vivo have been determined by employing the Michaelis-Menten rate equation; it was found that maximum metabolizing capacity was 8.33 mmole PD/kg/hr in the rat, which is equivalent to 1.06 kg/day for an average 70-kg human.",Kinetics of propylene glycol elimination and metabolism in rat. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3355719/),[kg] / [d],1.06,115699,DB00157,NADH
,3355719,Km,The rate equation could be suitably used for optimizing the dosage schedule of a drug from the linear elimination pattern; in the present case this gave a Km value of 17.86 mmole/kg on the basis of the elimination rate of PD.,Kinetics of propylene glycol elimination and metabolism in rat. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3355719/),[mmole] / [kg],17.86,115700,DB00157,NADH
,3355719,Ki,The competitive inhibition of PD elimination by preadministration of pyrazole (Ki = 44 mumole/kg) demonstrated that the first step of the biotransformation of PD catalyzed by the NAD-dependent dehydrogenase might be the rate-limiting step for its in vivo metabolism.,Kinetics of propylene glycol elimination and metabolism in rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3355719/),[mumole] / [kg],44,115701,DB00157,NADH
,17680234,Percent urinary elimination,"Percent urinary elimination was observed to be 10.02 +/- 2.48, 11.2 +/- 1.66, and 13.24 +/- 5.79 (mean +/- SEM) respectively.","Tissue distribution and elimination of N-methyl-N-2,4,6-tetranitroaniline (tetryl) in rats. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17680234/),,10.02,123599,DB00157,NADH
,17680234,Percent urinary elimination,"Percent urinary elimination was observed to be 10.02 +/- 2.48, 11.2 +/- 1.66, and 13.24 +/- 5.79 (mean +/- SEM) respectively.","Tissue distribution and elimination of N-methyl-N-2,4,6-tetranitroaniline (tetryl) in rats. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17680234/),,11.2,123600,DB00157,NADH
,17680234,Percent urinary elimination,"Percent urinary elimination was observed to be 10.02 +/- 2.48, 11.2 +/- 1.66, and 13.24 +/- 5.79 (mean +/- SEM) respectively.","Tissue distribution and elimination of N-methyl-N-2,4,6-tetranitroaniline (tetryl) in rats. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17680234/),,13.24,123601,DB00157,NADH
,17680234,Percent fecal elimination,"Percent fecal elimination was 15.68 +/- 6.13, 9.41 +/- 1.52, and 8.45 +/- 1.81 respectively.","Tissue distribution and elimination of N-methyl-N-2,4,6-tetranitroaniline (tetryl) in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17680234/),,15.68,123602,DB00157,NADH
,17680234,Percent fecal elimination,"Percent fecal elimination was 15.68 +/- 6.13, 9.41 +/- 1.52, and 8.45 +/- 1.81 respectively.","Tissue distribution and elimination of N-methyl-N-2,4,6-tetranitroaniline (tetryl) in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17680234/),,9.41,123603,DB00157,NADH
,17680234,Percent fecal elimination,"Percent fecal elimination was 15.68 +/- 6.13, 9.41 +/- 1.52, and 8.45 +/- 1.81 respectively.","Tissue distribution and elimination of N-methyl-N-2,4,6-tetranitroaniline (tetryl) in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17680234/),,8.45,123604,DB00157,NADH
,15498501,plasma half-life,"Compound 3 was not metabolised by murine whole blood in vitro (in contrast to compounds 2, 11 and EO9) and pharmacokinetic studies in non-tumour-bearing mice in vivo (at the maximum soluble dose of 60 mg kg(-1) administered intraperitoneally) demonstrated significant improvements in plasma half-life (16.2 min) and AUC values (22.5 microM h) compared to EO9 (T(1/2) = 1.8 min, AUC = 0.184 microM h).","Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15498501/),min,16.2,125400,DB00157,NADH
,15498501,AUC,"Compound 3 was not metabolised by murine whole blood in vitro (in contrast to compounds 2, 11 and EO9) and pharmacokinetic studies in non-tumour-bearing mice in vivo (at the maximum soluble dose of 60 mg kg(-1) administered intraperitoneally) demonstrated significant improvements in plasma half-life (16.2 min) and AUC values (22.5 microM h) compared to EO9 (T(1/2) = 1.8 min, AUC = 0.184 microM h).","Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15498501/),h·μM,22.5,125401,DB00157,NADH
,15498501,T(1/2),"Compound 3 was not metabolised by murine whole blood in vitro (in contrast to compounds 2, 11 and EO9) and pharmacokinetic studies in non-tumour-bearing mice in vivo (at the maximum soluble dose of 60 mg kg(-1) administered intraperitoneally) demonstrated significant improvements in plasma half-life (16.2 min) and AUC values (22.5 microM h) compared to EO9 (T(1/2) = 1.8 min, AUC = 0.184 microM h).","Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15498501/),min,1.8,125402,DB00157,NADH
,15498501,AUC,"Compound 3 was not metabolised by murine whole blood in vitro (in contrast to compounds 2, 11 and EO9) and pharmacokinetic studies in non-tumour-bearing mice in vivo (at the maximum soluble dose of 60 mg kg(-1) administered intraperitoneally) demonstrated significant improvements in plasma half-life (16.2 min) and AUC values (22.5 microM h) compared to EO9 (T(1/2) = 1.8 min, AUC = 0.184 microM h).","Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15498501/),h·μM,0.184,125403,DB00157,NADH
,3789759,Vmax,The Vmax (nmol/mg protein/min) of DHU (dihydrouracil dehydrogenase) in the liver homogenate from normal mice was 1.18 and found to be 0.70 in CCl4-treated mice.,"[Dose, administration time and route and hepatic function-dependent metabolism of 5-FU in mice]. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3789759/),[nM] / [·mg·min],1.18,138131,DB00157,NADH
,3789759,Vmax,The Vmax (nmol/mg protein/min) of DHU (dihydrouracil dehydrogenase) in the liver homogenate from normal mice was 1.18 and found to be 0.70 in CCl4-treated mice.,"[Dose, administration time and route and hepatic function-dependent metabolism of 5-FU in mice]. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3789759/),[nM] / [·mg·min],0.70,138132,DB00157,NADH
,26265043,AUC0-24h,"The AUC0-24h was 195.5 h/nmol/l, the terminal elimination half-life was 10.2 h, and the kel was 0.068 h(-1).","Pharmacokinetics and pharmacodynamics of orally administered acetylenic tricyclic bis(cyanoenone), a highly potent Nrf2 activator with a reversible covalent mode of action. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26265043/),[h] / [l·nM],195.5,147881,DB00157,NADH
,26265043,terminal elimination half-life,"The AUC0-24h was 195.5 h/nmol/l, the terminal elimination half-life was 10.2 h, and the kel was 0.068 h(-1).","Pharmacokinetics and pharmacodynamics of orally administered acetylenic tricyclic bis(cyanoenone), a highly potent Nrf2 activator with a reversible covalent mode of action. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26265043/),h,10.2,147882,DB00157,NADH
,26265043,kel,"The AUC0-24h was 195.5 h/nmol/l, the terminal elimination half-life was 10.2 h, and the kel was 0.068 h(-1).","Pharmacokinetics and pharmacodynamics of orally administered acetylenic tricyclic bis(cyanoenone), a highly potent Nrf2 activator with a reversible covalent mode of action. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26265043/),1/[h],0.068,147883,DB00157,NADH
,10718341,t1/2,"Pharmacokinetic analysis of RH1 in mice showed a t1/2 of 23 min with an area under the curve of 43.0 ng hr mL(-1) resulting in a calculated clearance of 5.1 mL min(-1), 10-fold slower than EO9.","Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10718341/),min,23,148619,DB00157,NADH
,10718341,area under the curve,"Pharmacokinetic analysis of RH1 in mice showed a t1/2 of 23 min with an area under the curve of 43.0 ng hr mL(-1) resulting in a calculated clearance of 5.1 mL min(-1), 10-fold slower than EO9.","Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10718341/),[h·ng] / [ml],43.0,148620,DB00157,NADH
,10718341,clearance,"Pharmacokinetic analysis of RH1 in mice showed a t1/2 of 23 min with an area under the curve of 43.0 ng hr mL(-1) resulting in a calculated clearance of 5.1 mL min(-1), 10-fold slower than EO9.","Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10718341/),[ml] / [min],5.1,148621,DB00157,NADH
,10718341,metabolic rate,"DTD activity in the kidney cytosol was high (125+/-8.2 nmol/mg/min) and EO9 was rapidly metabolised (4396+/-1678 pmol/min/g), but the metabolic rate for RH1 was 7-fold slower (608+/-86 pmol/min/g), even though RH1 was shown to be an excellent substrate for DTD (Vmax = 800 micromol/min/mg and a Km of 11.8 microM).","Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10718341/),[pM] / [g·min],608,148622,DB00157,NADH
,10718341,Vmax,"DTD activity in the kidney cytosol was high (125+/-8.2 nmol/mg/min) and EO9 was rapidly metabolised (4396+/-1678 pmol/min/g), but the metabolic rate for RH1 was 7-fold slower (608+/-86 pmol/min/g), even though RH1 was shown to be an excellent substrate for DTD (Vmax = 800 micromol/min/mg and a Km of 11.8 microM).","Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10718341/),[μM] / [mg·min],800,148623,DB00157,NADH
,10718341,Km,"DTD activity in the kidney cytosol was high (125+/-8.2 nmol/mg/min) and EO9 was rapidly metabolised (4396+/-1678 pmol/min/g), but the metabolic rate for RH1 was 7-fold slower (608+/-86 pmol/min/g), even though RH1 was shown to be an excellent substrate for DTD (Vmax = 800 micromol/min/mg and a Km of 11.8 microM).","Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10718341/),μM,11.8,148624,DB00157,NADH
,6356161,Km,"At pH 7.5, Km values for ethanol and Vmax values range 0.048 mM and 9 min-1 for beta 1 beta 1 to 64 mM and 560 min-1 for beta ind beta ind, respectively.",Relationship between kinetics of liver alcohol dehydrogenase and alcohol metabolism. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6356161/),mM,0.048,150532,DB00157,NADH
,6356161,Km,"At pH 7.5, Km values for ethanol and Vmax values range 0.048 mM and 9 min-1 for beta 1 beta 1 to 64 mM and 560 min-1 for beta ind beta ind, respectively.",Relationship between kinetics of liver alcohol dehydrogenase and alcohol metabolism. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6356161/),1/[min],9,150533,DB00157,NADH
,6356161,Km,"At pH 7.5, Km values for ethanol and Vmax values range 0.048 mM and 9 min-1 for beta 1 beta 1 to 64 mM and 560 min-1 for beta ind beta ind, respectively.",Relationship between kinetics of liver alcohol dehydrogenase and alcohol metabolism. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6356161/),mM,64,150534,DB00157,NADH
,6356161,Km,"At pH 7.5, Km values for ethanol and Vmax values range 0.048 mM and 9 min-1 for beta 1 beta 1 to 64 mM and 560 min-1 for beta ind beta ind, respectively.",Relationship between kinetics of liver alcohol dehydrogenase and alcohol metabolism. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6356161/),1/[min],560,150535,DB00157,NADH
,6356161,Vmax,"At pH 7.5, Km values for ethanol and Vmax values range 0.048 mM and 9 min-1 for beta 1 beta 1 to 64 mM and 560 min-1 for beta ind beta ind, respectively.",Relationship between kinetics of liver alcohol dehydrogenase and alcohol metabolism. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6356161/),mM,0.048,150536,DB00157,NADH
,6356161,Vmax,"At pH 7.5, Km values for ethanol and Vmax values range 0.048 mM and 9 min-1 for beta 1 beta 1 to 64 mM and 560 min-1 for beta ind beta ind, respectively.",Relationship between kinetics of liver alcohol dehydrogenase and alcohol metabolism. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6356161/),1/[min],9,150537,DB00157,NADH
,6356161,Vmax,"At pH 7.5, Km values for ethanol and Vmax values range 0.048 mM and 9 min-1 for beta 1 beta 1 to 64 mM and 560 min-1 for beta ind beta ind, respectively.",Relationship between kinetics of liver alcohol dehydrogenase and alcohol metabolism. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6356161/),mM,64,150538,DB00157,NADH
,6356161,Vmax,"At pH 7.5, Km values for ethanol and Vmax values range 0.048 mM and 9 min-1 for beta 1 beta 1 to 64 mM and 560 min-1 for beta ind beta ind, respectively.",Relationship between kinetics of liver alcohol dehydrogenase and alcohol metabolism. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6356161/),1/[min],560,150539,DB00157,NADH
,25217335,Ki,"The pharmacokinetics (PK) and pharmacodynamics (PD) of PT119, a potent Staphylococcus aureus enoyl-ACP reductase (saFabI) inhibitor with a Ki value of 0.01 nM and a residence time of 750 min on the enzyme target, has been evaluated in mice.",Radiosynthesis and biological evaluation of a novel enoyl-ACP reductase inhibitor for Staphylococcus aureus. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25217335/),nM,0.01,152064,DB00157,NADH
,25217335,residence time,"The pharmacokinetics (PK) and pharmacodynamics (PD) of PT119, a potent Staphylococcus aureus enoyl-ACP reductase (saFabI) inhibitor with a Ki value of 0.01 nM and a residence time of 750 min on the enzyme target, has been evaluated in mice.",Radiosynthesis and biological evaluation of a novel enoyl-ACP reductase inhibitor for Staphylococcus aureus. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25217335/),min,750,152065,DB00157,NADH
,19369827,steady-state plasma levels,GMX1777 at a dose of 75 mg/kg administered over a 24 h intravenous infusion produced GMX1778 steady-state plasma levels of approximately 1 microg/ml and caused nicotinamide adenine dinucleotide levels to decrease significantly in tumors.,Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19369827/),[μg] / [ml],1,159405,DB00157,NADH
,17121188,peak plasma concentration,The peak plasma concentration of BHA achieved in our current study after oral administration of 200 mg/kg BHA was around 10 microM.,"In vivo pharmacokinetics, activation of MAPK signaling and induction of phase II/III drug metabolizing enzymes/transporters by cancer chemopreventive compound BHA in the mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17121188/),μM,10,165574,DB00157,NADH
,17121188,oral bioavailability (F),The oral bioavailability (F) of BHA was about 43% in the mice.,"In vivo pharmacokinetics, activation of MAPK signaling and induction of phase II/III drug metabolizing enzymes/transporters by cancer chemopreventive compound BHA in the mice. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17121188/),%,43,165575,DB00157,NADH
,25037916,IC50,Biochemical and surface plasmon resonance experiments performed with a screening hit (LDHA IC50=1.7 μM) indicated that the compound specifically associated with human LDHA in a manner that required simultaneous binding of the NADH co-factor.,Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25037916/),μM,1.7,174890,DB00157,NADH
,25037916,IC50,Structural variation of this screening hit resulted in significant improvements in LDHA biochemical inhibition activity (best IC50=0.18 μM).,Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25037916/),μM,0.18,174891,DB00157,NADH
,25037916,F,"In addition, an optimized inhibitor exhibited good pharmacokinetic properties after oral administration to rats (F=45%).",Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25037916/),%,45,174892,DB00157,NADH
,8070006,initial half-life,The initial half-life increased significantly (P < 0.05) from 0.8 to 2 h and the terminal half-life increased from 3.4 to 5.6 h over the dose range studied.,Pharmacokinetics and biochemistry studies on nicotinamide in the mouse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070006/),h,0.8 to 2,181067,DB00157,NADH
,8070006,terminal half-life,The initial half-life increased significantly (P < 0.05) from 0.8 to 2 h and the terminal half-life increased from 3.4 to 5.6 h over the dose range studied.,Pharmacokinetics and biochemistry studies on nicotinamide in the mouse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070006/),h,3.4 to 5.6,181068,DB00157,NADH
,8070006,Clearance,"Clearance, however, decreased significantly from 0.3 to 0.24 l kg-1 h-1 only at the highest dose.",Pharmacokinetics and biochemistry studies on nicotinamide in the mouse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070006/),[l] / [h·kg],0.3,181069,DB00157,NADH
,8070006,Clearance,"Clearance, however, decreased significantly from 0.3 to 0.24 l kg-1 h-1 only at the highest dose.",Pharmacokinetics and biochemistry studies on nicotinamide in the mouse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070006/),[l] / [h·kg],0.24,181070,DB00157,NADH
,8070006,Peak concentrations,"Peak concentrations increased in a dose-dependent manner from 1,000 to 4,800 nmol/ml.",Pharmacokinetics and biochemistry studies on nicotinamide in the mouse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070006/),[nM] / [ml],"1,",181071,DB00157,NADH
,8070006,peak concentration,"The main plasma metabolite in the mouse is nicotinamide N-oxide, the peak concentration of which increased only from 80 to 160 nmol/ml.",Pharmacokinetics and biochemistry studies on nicotinamide in the mouse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070006/),[nM] / [ml],80,181072,DB00157,NADH
,8070006,peak concentration,"The main plasma metabolite in the mouse is nicotinamide N-oxide, the peak concentration of which increased only from 80 to 160 nmol/ml.",Pharmacokinetics and biochemistry studies on nicotinamide in the mouse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070006/),[nM] / [ml],160,181073,DB00157,NADH
,8070006,peak concentrations,"The N-oxide, which is also a weak radiosensitizer, is subject to reduction to the parent nicotinamide following administration at a dose of 276 mg/kg; peak concentrations of the N-oxide of 1900 nmol/ml were reached in 10 min, whereas concentrations of nicotinamide produced by reduction reached a maximum of 144 nmol/ml at 1 h.",Pharmacokinetics and biochemistry studies on nicotinamide in the mouse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070006/),[nM] / [ml],1900,181074,DB00157,NADH
,8070006,peak concentrations,"The N-oxide, which is also a weak radiosensitizer, is subject to reduction to the parent nicotinamide following administration at a dose of 276 mg/kg; peak concentrations of the N-oxide of 1900 nmol/ml were reached in 10 min, whereas concentrations of nicotinamide produced by reduction reached a maximum of 144 nmol/ml at 1 h.",Pharmacokinetics and biochemistry studies on nicotinamide in the mouse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070006/),nm,144,181075,DB00157,NADH
,8070006,initial,"Elimination of the N-oxide was also biphasic, with initial and terminal half-lives being 0.39 and 1.8 h, respectively.",Pharmacokinetics and biochemistry studies on nicotinamide in the mouse. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070006/),h,0.39,181076,DB00157,NADH
,8070006,terminal half-lives,"Elimination of the N-oxide was also biphasic, with initial and terminal half-lives being 0.39 and 1.8 h, respectively.",Pharmacokinetics and biochemistry studies on nicotinamide in the mouse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070006/),h,1.8,181077,DB00157,NADH
,8070006,bioavailability,The bioavailability of both drugs given via the i.p. as compared with the i.v. route was close to 100%.,Pharmacokinetics and biochemistry studies on nicotinamide in the mouse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070006/),%,100,181078,DB00157,NADH
,18508468,absorption rate,"In the gut sac, NADH had a concentration-independent absorption rate of about 5 percent and the in vivo laser-induced fluorescence spectroscopy revealed a relatively quick absorption of NADH starting after a few minute reaching a plateau (about 5 percent ) after 20-30 minutes.",Pharmacokinetic aspects of reduced nicotinamide adenine dinucleotide (NADH) in rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18508468/),%,5,181677,DB00157,NADH
,29066863,maximum plasma concentration (Cmax),"Following a single 100 mg MB12066 oral dose, maximum plasma concentration (Cmax) of β-lapachone was 3.56±1.55 ng/mL, and the median (range) time to reach Cmax was 3 h (2-5 h).","Pharmacokinetic and safety evaluation of MB12066, an NQO1 substrate. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29066863/),[ng] / [ml],3.56,183112,DB00157,NADH
,29066863,time to reach Cmax,"Following a single 100 mg MB12066 oral dose, maximum plasma concentration (Cmax) of β-lapachone was 3.56±1.55 ng/mL, and the median (range) time to reach Cmax was 3 h (2-5 h).","Pharmacokinetic and safety evaluation of MB12066, an NQO1 substrate. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29066863/),h,3,183113,DB00157,NADH
,29066863,terminal half-life,"After the 8 days of 100 mg twice daily repeated dosing was completed, mean terminal half-life was determined to be 18.16±3.14 h, and the mean area under the plasma concentration vs time curve at steady state was 50.44±29.68 ng·h/mL.","Pharmacokinetic and safety evaluation of MB12066, an NQO1 substrate. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29066863/),h,18.16,183114,DB00157,NADH
,29066863,area under the plasma concentration vs time curve at steady state,"After the 8 days of 100 mg twice daily repeated dosing was completed, mean terminal half-life was determined to be 18.16±3.14 h, and the mean area under the plasma concentration vs time curve at steady state was 50.44±29.68 ng·h/mL.","Pharmacokinetic and safety evaluation of MB12066, an NQO1 substrate. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29066863/),[h·ng] / [ml],50.44,183115,DB00157,NADH
,29066863,Accumulation index,Accumulation index was 2.72±0.37.,"Pharmacokinetic and safety evaluation of MB12066, an NQO1 substrate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29066863/),,2.72,183116,DB00157,NADH
,29066863,accumulation ratio,Accumulation in plasma with twice-daily administration was associated with a 2.72 accumulation ratio.,"Pharmacokinetic and safety evaluation of MB12066, an NQO1 substrate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29066863/),,2.72,183117,DB00157,NADH
,22948878,MIC(90),"AFN-1252 demonstrated a low propensity for spontaneous resistance development and a time-dependent reduction of the viability of both methicillin-susceptible and methicillin-resistant S. aureus, achieving a ≥2-log(10) reduction in S. aureus counts over 24 h, and was extremely potent against clinical isolates of S. aureus (MIC(90), 0.015 μg/ml) and coagulase-negative staphylococci (MIC(90), 0.12 μg/ml), regardless of their drug resistance, hospital- or community-associated origin, or other clinical subgroup.","Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22948878/),[μg] / [ml],0.015,201998,DB00157,NADH
,22948878,MIC(90),"AFN-1252 demonstrated a low propensity for spontaneous resistance development and a time-dependent reduction of the viability of both methicillin-susceptible and methicillin-resistant S. aureus, achieving a ≥2-log(10) reduction in S. aureus counts over 24 h, and was extremely potent against clinical isolates of S. aureus (MIC(90), 0.015 μg/ml) and coagulase-negative staphylococci (MIC(90), 0.12 μg/ml), regardless of their drug resistance, hospital- or community-associated origin, or other clinical subgroup.","Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22948878/),[μg] / [ml],0.12,201999,DB00157,NADH
,8421321,time to maximum plasma concentration (Tmax),"When CHN alone was administered orally, the time to maximum plasma concentration (Tmax) of CHN was as short as 15 min, but that of CHL was 120 min.",Metabolic interaction of ethanol and cyclohexanone in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8421321/),min,15,209236,DB00157,NADH
,8421321,time to maximum plasma concentration (Tmax),"When CHN alone was administered orally, the time to maximum plasma concentration (Tmax) of CHN was as short as 15 min, but that of CHL was 120 min.",Metabolic interaction of ethanol and cyclohexanone in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8421321/),min,120,209237,DB00157,NADH
,9483171,plasma half-life,The plasma half-life of phenprocoumon was approximately 350 h (normal 120-150 h).,Vitamin K metabolism in a patient resistant to vitamin K antagonists. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9483171/),h,350,209422,DB00157,NADH
,31035043,maximum plasma concentration (Cmax),"After a single oral administration of 50 mg/kg deAND to rats, the maximum plasma concentration (Cmax), time to reach the Cmax, area under the curve (AUC0-24h), mean retention time, and half-life (t1/2) of deAND were 2.65 ± 0.68 μg/ml, 0.29 ± 0.15 h, 6.30 ± 1.66 μg/ml•h, 5.55 ± 2.52 h, and 3.56 ± 1.05 h, respectively.","Bioavailability of the diterpenoid 14-deoxy-11,12-didehydroandrographolide in rats and up-regulation of hepatic drug-metabolizing enzyme and drug transporter expression. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31035043/),[μg] / [ml],2.65,210459,DB00157,NADH
,31035043,area under the curve (AUC0-24h),"After a single oral administration of 50 mg/kg deAND to rats, the maximum plasma concentration (Cmax), time to reach the Cmax, area under the curve (AUC0-24h), mean retention time, and half-life (t1/2) of deAND were 2.65 ± 0.68 μg/ml, 0.29 ± 0.15 h, 6.30 ± 1.66 μg/ml•h, 5.55 ± 2.52 h, and 3.56 ± 1.05 h, respectively.","Bioavailability of the diterpenoid 14-deoxy-11,12-didehydroandrographolide in rats and up-regulation of hepatic drug-metabolizing enzyme and drug transporter expression. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31035043/),h,5.55,210460,DB00157,NADH
,31035043,mean retention time,"After a single oral administration of 50 mg/kg deAND to rats, the maximum plasma concentration (Cmax), time to reach the Cmax, area under the curve (AUC0-24h), mean retention time, and half-life (t1/2) of deAND were 2.65 ± 0.68 μg/ml, 0.29 ± 0.15 h, 6.30 ± 1.66 μg/ml•h, 5.55 ± 2.52 h, and 3.56 ± 1.05 h, respectively.","Bioavailability of the diterpenoid 14-deoxy-11,12-didehydroandrographolide in rats and up-regulation of hepatic drug-metabolizing enzyme and drug transporter expression. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31035043/),h,5.55,210461,DB00157,NADH
,31035043,half-life (t1/2),"After a single oral administration of 50 mg/kg deAND to rats, the maximum plasma concentration (Cmax), time to reach the Cmax, area under the curve (AUC0-24h), mean retention time, and half-life (t1/2) of deAND were 2.65 ± 0.68 μg/ml, 0.29 ± 0.15 h, 6.30 ± 1.66 μg/ml•h, 5.55 ± 2.52 h, and 3.56 ± 1.05 h, respectively.","Bioavailability of the diterpenoid 14-deoxy-11,12-didehydroandrographolide in rats and up-regulation of hepatic drug-metabolizing enzyme and drug transporter expression. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31035043/),h,3.56,210462,DB00157,NADH
,31035043,oral bioavailability,The oral bioavailability was 3.42%.,"Bioavailability of the diterpenoid 14-deoxy-11,12-didehydroandrographolide in rats and up-regulation of hepatic drug-metabolizing enzyme and drug transporter expression. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31035043/),%,3.42,210463,DB00157,NADH
,23284689,Tmax,Mean Tmax was 2-4 hours with elimination half-life of 15-20 hours.,"A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23284689/),h,2-4,213643,DB00157,NADH
,23284689,elimination half-life,Mean Tmax was 2-4 hours with elimination half-life of 15-20 hours.,"A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23284689/),h,15-20,213644,DB00157,NADH
,7018678,alpha-phase half-life,"The alpha-phase half-life of LV was about 15 mins, but LV was readily detectable by the assay for 3-4 hrs.",Pharmacokinetics of leucovorin rescue using a new methotrexate-independent biochemical assay for leucovorin and N5-methyltetrahydrofolate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7018678/),min,15,218709,DB00157,NADH
,7018678,apparent half-life,"The level of mTHFA increased for at least 60 mins, being equimolar with LV by 30 mins, and then decreased slowly with an apparent half-life of 2-3 hrs.",Pharmacokinetics of leucovorin rescue using a new methotrexate-independent biochemical assay for leucovorin and N5-methyltetrahydrofolate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7018678/),h,2-3,218710,DB00157,NADH
,23525756,half-life,"Pharmacokinetic exposures were linear and dose-dependent, with a half-life of approximately 5 h.","A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23525756/),h,5,220017,DB00157,NADH
,22634319,MTD,The MTD was established as 900 mg/d.,A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22634319/),[mg] / [d],900,243111,DB00157,NADH
,22634319,MTD,Bardoxolone methyl was well tolerated with an MTD of 900 mg/d.,A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22634319/),[mg] / [d],900,243112,DB00157,NADH
,31638799,GI50,"The thus-optimized DS18561882 showed the strongest cell-based activity (GI50 = 140 nM) in the class, a good oral pharmacokinetic profile, and thereby tumor growth inhibition in a mouse xenograft model upon oral administration.","Discovery of a Potent, Selective, and Orally Available MTHFD2 Inhibitor (DS18561882) with in Vivo Antitumor Activity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31638799/),nM,140,244172,DB00157,NADH
,1282174,bioavailability,"Thus, it easily enters the systemic blood flow, resulting in almost complete bioavailability (75-100%).",Pharmacokinetic profile of nicorandil in humans: an overview. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282174/),%,75-100,258555,DB00157,NADH
,1282174,Cmax,"On average, the Cmax then is approximately 300 ng/ml, which is achieved rapidly within 30 min after drug intake.",Pharmacokinetic profile of nicorandil in humans: an overview. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282174/),[ng] / [ml],300,258556,DB00157,NADH
,1282174,apparent volume of distribution,"After oral (and i.v.) administration of the drug, the apparent volume of distribution is approximately 1.0 L/kg body weight.",Pharmacokinetic profile of nicorandil in humans: an overview. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282174/),[l] / [body·kg·weight],1.0,258557,DB00157,NADH
,1282174,apparent elimination half-life,"The apparent elimination half-life is short (approximately 1 h), and total body clearance is close to 1.15 L/min, which is lower than the liver blood flow.",Pharmacokinetic profile of nicorandil in humans: an overview. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282174/),h,1,258558,DB00157,NADH
,1282174,total body clearance,"The apparent elimination half-life is short (approximately 1 h), and total body clearance is close to 1.15 L/min, which is lower than the liver blood flow.",Pharmacokinetic profile of nicorandil in humans: an overview. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282174/),[l] / [min],1.15,258559,DB00157,NADH
,7957446,AUC0-infinity,"In severely uraemic patients, median AUC0-infinity was multiplied by a factor of about 2: 40.5 mg.h/l versus 21.3 mg.h/l in healthy subjects, P = 0.04; and t1/2 was prolonged by the same factor: 9.6 h versus 4.3 h in the control group, P = 0.003.",Influence of renal function on the pharmacokinetics of diacerein after a single oral dose. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957446/),[h·mg] / [l],40.5,269094,DB00157,NADH
,7957446,AUC0-infinity,"In severely uraemic patients, median AUC0-infinity was multiplied by a factor of about 2: 40.5 mg.h/l versus 21.3 mg.h/l in healthy subjects, P = 0.04; and t1/2 was prolonged by the same factor: 9.6 h versus 4.3 h in the control group, P = 0.003.",Influence of renal function on the pharmacokinetics of diacerein after a single oral dose. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957446/),[h·mg] / [l],21.3,269095,DB00157,NADH
,7957446,t1/2,"In severely uraemic patients, median AUC0-infinity was multiplied by a factor of about 2: 40.5 mg.h/l versus 21.3 mg.h/l in healthy subjects, P = 0.04; and t1/2 was prolonged by the same factor: 9.6 h versus 4.3 h in the control group, P = 0.003.",Influence of renal function on the pharmacokinetics of diacerein after a single oral dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957446/),h,9.6,269096,DB00157,NADH
,7957446,t1/2,"In severely uraemic patients, median AUC0-infinity was multiplied by a factor of about 2: 40.5 mg.h/l versus 21.3 mg.h/l in healthy subjects, P = 0.04; and t1/2 was prolonged by the same factor: 9.6 h versus 4.3 h in the control group, P = 0.003.",Influence of renal function on the pharmacokinetics of diacerein after a single oral dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957446/),h,4.3,269097,DB00157,NADH
,7957446,Apparent drug availability,"Apparent drug availability and renal clearance assessed through urinary data decreased with renal failure, respectively: 14.5% and 0.045 l/h versus 35.4% (P = 0.01) and 0.13 l/h (P = 0.008) in healthy subjects.",Influence of renal function on the pharmacokinetics of diacerein after a single oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957446/),%,14.5,269098,DB00157,NADH
,7957446,Apparent drug availability,"Apparent drug availability and renal clearance assessed through urinary data decreased with renal failure, respectively: 14.5% and 0.045 l/h versus 35.4% (P = 0.01) and 0.13 l/h (P = 0.008) in healthy subjects.",Influence of renal function on the pharmacokinetics of diacerein after a single oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957446/),%,35.4,269099,DB00157,NADH
,7957446,renal clearance,"Apparent drug availability and renal clearance assessed through urinary data decreased with renal failure, respectively: 14.5% and 0.045 l/h versus 35.4% (P = 0.01) and 0.13 l/h (P = 0.008) in healthy subjects.",Influence of renal function on the pharmacokinetics of diacerein after a single oral dose. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957446/),[l] / [h],0.045,269100,DB00157,NADH
,7957446,renal clearance,"Apparent drug availability and renal clearance assessed through urinary data decreased with renal failure, respectively: 14.5% and 0.045 l/h versus 35.4% (P = 0.01) and 0.13 l/h (P = 0.008) in healthy subjects.",Influence of renal function on the pharmacokinetics of diacerein after a single oral dose. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957446/),[l] / [h],0.13,269101,DB00157,NADH
,27083855,brain/serum ratio,"Pharmacokinetics of MDAI was rapid, maximum median concentration in serum and brain was attained 30min and almost returned to zero 6h after subcutaneous (sc.) administration of 10mg/kg MDAI; brain/serum ratio was ~4.","Emerging toxicity of 5,6-methylenedioxy-2-aminoindane (MDAI): Pharmacokinetics, behaviour, thermoregulation and LD50 in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27083855/),,4,269509,DB00157,NADH
,9010628,bioavailability,"After oral administration, D2624 was found to be well absorbed (93%), but underwent extensive first-pass metabolism in the rat, thus resulting in 5.3% bioavailability.","Pharmacokinetics and metabolism of the novel anticonvulsant agent N-(2,6-dimethylphenyl)-5-methyl-3-isoxazolecarboxamide (D2624) in rats and humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010628/),%,5.3,269986,DB00157,NADH
,9010628,half-life,"D3017 was detected after all doses of parent drug, with approximate dose proportionality in AUC and a half-life of 1.3-2.2 hr.","Pharmacokinetics and metabolism of the novel anticonvulsant agent N-(2,6-dimethylphenyl)-5-methyl-3-isoxazolecarboxamide (D2624) in rats and humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010628/),h,1.3-2.2,269987,DB00157,NADH
,27718143,plasma concentration,The difference in plasma concentration of donepezil after 12 h (mean ± SEM; 39.99 ± 5.90 ng/ml) and after 24 h (29.38 ± 1.71 ng/ml) was nonsignificant.,Concentration of Donepezil in the Cerebrospinal Fluid of AD Patients: Evaluation of Dosage Sufficiency in Standard Treatment Strategy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27718143/),[ng] / [ml],39.,272432,DB00157,NADH
,27718143,plasma concentration,The difference in plasma concentration of donepezil after 12 h (mean ± SEM; 39.99 ± 5.90 ng/ml) and after 24 h (29.38 ± 1.71 ng/ml) was nonsignificant.,Concentration of Donepezil in the Cerebrospinal Fluid of AD Patients: Evaluation of Dosage Sufficiency in Standard Treatment Strategy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27718143/),ng,29,272433,DB00157,NADH
,27718143,concentration,"In contrast, the donepezil concentration in the cerebrospinal fluid was significantly higher in the 24-h interval (7.54 ± 0.55 ng/ml) compared with the 12-h interval (5.19 ± 0.83 ng/ml, which is ~70 % based on mean cerebrospinal fluid values).",Concentration of Donepezil in the Cerebrospinal Fluid of AD Patients: Evaluation of Dosage Sufficiency in Standard Treatment Strategy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27718143/),ng,7,272434,DB00157,NADH
,27718143,concentration,"In contrast, the donepezil concentration in the cerebrospinal fluid was significantly higher in the 24-h interval (7.54 ± 0.55 ng/ml) compared with the 12-h interval (5.19 ± 0.83 ng/ml, which is ~70 % based on mean cerebrospinal fluid values).",Concentration of Donepezil in the Cerebrospinal Fluid of AD Patients: Evaluation of Dosage Sufficiency in Standard Treatment Strategy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27718143/),ng,5,272435,DB00157,NADH
,32020381,absolute bioavailability (F),"Compared to IV CUR, the absolute bioavailability (F) of CUR for GNC (GC) is 0.9%, Vitamin Shoppe (VC) is 0.6% and Sigma (SC) is 3.1%.",Pharmacokinetics and pharmacodynamics of three oral formulations of curcumin in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32020381/),%,0.9,274050,DB00157,NADH
,32020381,absolute bioavailability (F),"Compared to IV CUR, the absolute bioavailability (F) of CUR for GNC (GC) is 0.9%, Vitamin Shoppe (VC) is 0.6% and Sigma (SC) is 3.1%.",Pharmacokinetics and pharmacodynamics of three oral formulations of curcumin in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32020381/),%,0.6,274051,DB00157,NADH
,32020381,absolute bioavailability (F),"Compared to IV CUR, the absolute bioavailability (F) of CUR for GNC (GC) is 0.9%, Vitamin Shoppe (VC) is 0.6% and Sigma (SC) is 3.1%.",Pharmacokinetics and pharmacodynamics of three oral formulations of curcumin in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32020381/),%,3.1,274052,DB00157,NADH
